慈丹胶囊治疗原发性肝癌325例临床总结

观察慈丹胶囊治疗原发性肝癌的疗效,将325例肝癌患者随机分为中药组（慈丹胶囊）125例。中药加化疗组（慈丹胶囊加化疗）100例。化疗对照组（常规化疗）100例,疗程2个月,结果：中药加化疗组稳定及稳定以上率为87.0%,中药组为72.8%,化疗对照组为57.0%。患者生活质量改善对比中药加化疗组明显优于中药组和化疗对照组;治疗后NK细胞,CD3,CD4,CD8指标化疗对照组明显下降,中药加化疗组NK细胞,CD8指标下降幅度小,CD3,CD4无显著变化;治疗后AFP指标,中药组（118例）和中药加化疗组均明显下降。化疗对照组下降不明显,提示中药加化疗的疗效优于单纯化疗。

Clinical Summarization of "Cidan Capsule" in Treating 325 Cases of Primary Liver Cancer

To observe the clinical efficacy of " Cidan Capsule" in the treatment of primary liver cancer, 325 cases were randomized into three groups: group A in which 125 cases were treated by "Cidan Capsule", group B in which 100 cases were treated by " Cidan Capsule" and chemotherapy and group C in which 100 cases were treated by simple chemotherapy, with a coarse of 2 months. Results: The remission rate was 72.8% in group A, 87.0% in group B and 57.0% in group C; the life quality improved more obviously in group B than in group A and group C;after treatment, the NK cell,CD3,CD4 and CD8 fell strikingly in group C;in group B.the NK cell and CD8 fell least and CD3 and CD4 fell little; after treatment AFP dropped markedly in group A and group B,but little in group C. It is revealed that Chinese medicine and chemotherapy have better effects than simple chemotherapy.